September 30, 2025
UCLH launches new ovarian cancer surveillance service for women at high risk
University College London Hospitals NHS Foundation Trust (UCLH), in collaboration with the NHS North Central London Cancer Alliance (NCLCA) and GENinCode Plc, becomes the first hospital trust in the country to provide a new ovarian cancer (OC) surveillance testing service as part of its Familial Cancer Clinic. The service, in line with new NICE (National Institute for Health and Care Excellence) guidance1, is for women who have a high risk of ovarian cancer due to inherited BRCA1 or BRCA2 gene alterations, who wish to defer preventative surgery.
December 13, 2024
GENinCode partners with Genesupport SA for the ROCA® Test in Switzerland
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”) and risk of ovarian cancer (“OC”), announces its partnership with Genesupport SA, part of the Sonic Switzerland network of laboratories, to enable country-wide access to the ROCA® Test.
November 2, 2022
Ovarian cancer surveillance in women with faulty BRCA genes results in earlier stage diagnosis for those deferring preventive surgery
Regularly monitoring women with faulty BRCA genes that make them highly susceptible to ovarian cancer, results in earlier stage* diagnosis in those who want to defer preventive surgery, finds research published online in the Journal of Medical Genetics.
November 2, 2022
The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 | Journal of Medical Genetics (bmj.com)
A pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2
November 2, 2022
Monitoring for ovarian cancer in high-risk women is beneficial, Cancer Alliance funded research shows – North Central London Cancer Alliance (nclcanceralliance.nhs.uk)
Research published in the latest issue of the Journal of Medical Genetics concludes that regularly monitoring women who carry BRCA gene alterations does provide some benefits.
November 2, 2022
UCLH research shows monitoring for ovarian cancer in high-risk women is beneficial : University College London Hospitals NHS Foundation Trust
UCLH research shows monitoring for ovarian cancer in high-risk women is beneficial : University College London Hospitals NHS Foundation Trust
November 2, 2022
